mdg-annual-report-2013

Recommendations

Info

18 pipelinepipelinemarketed drugsindicationpre-clinicclinical phase IVeregen®Genital wartsdrug candidatesPancreatic cancerEndoTAG®-1Triple-negative breast cancerRhuDex®Autoimmune diseasesProstate cancerDC VaccinesAMLTCRCancerTABSLeukaemia andAutoimmune diseasesAAVLPVaccine candidatesChance of reachingthe market 1)< 10% < 15%1)Industrial average,estimates of Medigene AG
Medigene AG Annual <strong>report</strong> <strong>2013</strong> pipeline 19clinical phase II clinical phase III approval market< 30% < 70% < 90%
Page 6 and 7: 6 Interview with the Executive Boar
Page 8 and 9: 8 KapitelT … as in TRANSACTIONSDe
Page 10 and 11: 10 KapitelT … as in THERAPEUTIC A
Page 12 and 13: 12 KapitelT … as in T cellsTechno
Page 14 and 15: 14 KapitelT … as in teamworkJoini
Page 16 and 17: 16 KapitelT … as in TRENDFinancia
Page 20 and 21: 20productsVeregen®ProduCt Indicati
Page 22 and 23: 22productsRhuDex®Product Indikatio
Page 24 and 25: 24productsImmunotherapiesImmunother
Page 28: 28 the shareThe ShareShare price pe
Page 31 and 32: Medigene AG Annual report 2013 Kapi
Page 34 and 35: 34 GROUP MANAGEMENT’S DISCUSSION
Page 40: 40 GROUP MANAGEMENT’S DISCUSSION
Page 51 and 52: MEDIGENE AG ANNUAL REPORT 2013 GROU
Page 61 and 62: CONTENTCONSOLIDATED FINANCIAL STATE
Page 63 and 64: MEDIGENE AG ANNUAL REPORT 2013 CONS
Page 70 and 71:
70 NOTES TO THE CONSOLIDATED FINANC
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
100 NOTES TO THE CONSOLIDATED FINAN
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
126 AUDIT OPINIONAUDIT OPINIONWe is
Page 128 and 129:
128 RESPONSIBILITY STATEMENTRESPONS
Page 130 and 131:
130 REPORT OF THE SUPERVISORY BOARD
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
136 GLOSSARYGLOSSARYAAAVLPAdeno-ass
Page 138 and 139:
138 GLOSSARYEEBITDAEarnings before
Page 140 and 141:
140 GLOSSARYMMajor histocompatibili
Page 142 and 143:
142 GLOSSARYTecDAXIndex of the Germ
Page 144:
144 FINANCIAL CALENDAR/ TRADEMARKS/
show all

mdg-annual-report-2013

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?